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A highly enantioselective alkene methoxycarbonylation enables a 
concise synthesis of (S)-Flurbiprofen 
Gavin J. Harkness,[a] and Matthew L. Clarke*[a] 
Abstract: A highly enantioselective synthesis of (S)-Flurbiprofen 
methyl ester in two steps from commercially available 4-bromo-2-
fluoro-1,1’-biphenyl is shown. [PdCl2((S)-Xylyl-Phanephos)] catalyst 
is used to accomplish both Grignard cross-coupling and the highly 
enantioselective intermolecular methoxycarbonylation reaction.  
Introduction 
Flurbiprofen is one of the “profen” anti-inflammatories and is 
widely sold as a racemate.[1] However, some applications, 
including those that are expanding commercially, require a 
single enantiomer form of Flurbiprofen.[1b-c, 2] The enantiomers of 
Flurbiprofen do not undergo significant inversion in vivo.[1a, 1c, 3] 
Catalytic asymmetric syntheses of enantiomerically enriched 
Flurbiprofen are relatively rare and generally have some 
problems that would prevent scale-up; such as requiring quite a 
large number of steps and reagents that are generally not 
preferred at large scale.[4] It has long been recognised that direct 
conversion of alkenes to branched carboxylic acid derivatives is 
potentially a more attractive procedure for making various 
products, [5] including various profen type drugs have been made 
in this way industrially as racemates.[5b, 6]  
 
Hydroxycarbonylation and methoxycarbonylation of vinyl arenes 
has been a very challenging reaction to develop,[5e-f, 7] most likely 
due to difficulties with simultaneous control of enantio- and 
regioselectivity.[5g-i, 8] Palladium catalysts derived from certain 
Phanephos ligands[9d] represent leading catalysts for 
intermolecular enantioselective alkene carbonylation (Figure 
1).[9a-c] [Pd2Cl4(F24-Phanephos)] dimer,[9b] 2 di, was found to be 
an especially suitable catalyst for the methoxycarbonylation of 
styrene (typically around 80 % e.e. and near perfect 
regioselectivity). Other phanephos ligands tend to give similar 
enantioselectivities between 70 and 90 % in the 
methoxycarbonylation of styrene but with no regiocontrol. In 
order to study the use of this catalyst system in the synthesis of 
a real target, we have investigated the catalytic synthesis of (S)-
Flurbiprofen, and report these results here. 
Results and Discussion 
We first required reliable access to the vinyl arene, 3-fluoro-4-
phenylstyrene. This could be made by a Pd-catalysed cross-
coupling of vinyl magnesium bromide with 4-bromo-2-fluoro-1,1’- 
 
Figure 1. Pd-Phanephos catalysts for the hydroxy- / methoxycarbonylation of 
alkenes.  
biphenyl exploiting the same class of Pd-Phanephos catalysts 
that are used in carbonylation. However, low yields as well as 
forcing conditions made us seek an alternative synthesis 
(Scheme 1 (i)). We felt a preferable synthesis might make use of 
a vinyl electrophile and a more stable aromatic Grignard 
reagent.[10] Indeed, large scale syntheses of vinyl arenes from 
vinyl chloride have been carried out before.[11] We found that 
vinyl tosylate, readily available by the decomposition of 
tetrahydrofuran[12], was an easier to handle vinyl electrophile 
than gaseous but cheap vinyl chloride/bromide, and could be 
cross-coupled with 2-fluoro-1,1’-biphenyl magnesium bromide 
with good efficiency in the presence of 1 mol% (S)-1 mo or (R)-2 
mo (Scheme 1 (ii) and Table 1). To the best of our knowledge, 
this is the first example of vinyl tosylate being used in a Grignard 
cross-coupling reaction.  
 
 
Scheme 1. Three routes for the synthesis of vinyl arene, 3-fluoro-4-
phenylstyrene. Reaction conditions: (i) 1 mol% rac-1 mo, 2-MeTHF, 80 °C, 89 
h, 44 % yield; (ii) 1 mol% (S)-1 mo, 2-MeTHF, 20 °C, 17 h, up to 99 % yield, 
see Table 1; (iii) 1 mol% rac-1 mo, K2CO3 (3 equiv.), dioxane/H2O, 101 °C, 17 
h, 59 % isolated yield.  
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Isolation of pure product was complicated by the very apolar, 
soluble nature of the product and the homocoupling and 
hydrolysis by-products, 3’,3’’-difluoro-
[1,1’;4’,1’’;4’’,1’’’]quarterphenyl and 2-fluorobiphenyl (Table 1, 
Entries 2 and 6). However, we felt that these inert impurities 
could likely be removed from the final product. An alternative 
route involving an adaptation of the Suzuki reaction of 4-bromo-
2-fluoro-1,1’-biphenyl with vinylboronic acid pinacol ester[13] gave, 
after chromatography, pure alkene in 59 % yield using rac-1 mo 
(Scheme 1 (iii)), which was used to initially investigate the 
carbonylation reactions.  
   





Entry[a] Catalyst Catalyst 
Loading 
(mol%) 




1 (S)-1 mo 1 20 17 > 99 99[c] 
2[d][e] (S)-1 mo 1 20 17 > 99 [90][f] 






4 (S)-1 mo 0.1 50 3 > 99 65 
5[g] (R)-2 mo 1 20 19 > 99 82 
6[d][g][h] (R)-2 mo 1 20 17 > 99 [79][i] 
[a] Reactions were carried out on the scale of vinyl tosylate (0.50 mmol), Grignard 
reagent (0.60 mmol in 2-MeTHF, molarity determined by titration before use), 2-
MeTHF (1.0 mL) in Schlenk flasks under argon, unless otherwise noted. [b]	  
Conversions and yields were determined by 1H NMR using 1-methylnaphthalene 
as an internal standard [yield of isolated product in square brackets]. [c] Average 
yield of 13 experiments (t 17-21 h) = 92 %, see Table S2, entries 1-14. [d] No 
internal standard. [e] 0.76 mmol scale. [f] 90 % yield isolated with 2-fluorobiphenyl 
impurity; total product obtained = 68 %. [g] 0.25 mmol scale. [h] Reaction 
performed in a sealed microwave vial with crimp cap. [i] 79 % yield isolated with 
2-fluorobiphenyl impurity; total product obtained = 63 %.  
   
In previous work on hydroxycarbonylation and 
methoxycarbonylation of styrene[9a, 9b], [Pd2Cl4(F24-Phanephos)] 
dimer, 2di, was clearly identified as the best catalyst for this type 
of process in terms of productivity, rate, and due to giving very 
high regioselectivity. It was therefore examined and compared to 
other Pd-Phanephos catalysts in the hydroxycarbonylation of 3-
fluoro-4-phenylstyrene (Table 2). It is clear that, F24-Phanephos 
catalysts give the best results in hydroxycarbonylation of 3-
fluoro-4-phenylstyrene. High yields, as well as excellent 
regioselectivity towards the branched isomer were observed. In 
contrast to previous studies, the monomeric palladium complex 
(R)-2 mo gave higher enantioselectivity than the dipalladium 
complex (R)-2 di. The level of enantioselectivity using (R)-2 di is 
significantly lower than that observed with styrene (~ 80 % e.e.). 
Monomeric [PdCl2((S)-Xylyl-Phanephos)], (S)-1 mo, gave 
slightly higher enantioselectivity but low yield. All of the acid 
products could be isolated in pure form by simple acid-base 
extraction.  
   
Table 2. Synthesis of Flurbiprofen by enantioselective hydroxycarbonylation 
using Pd-Phanephos catalysts.  
 
 
Entry[a] Catalyst T (o C) Product[b] 
(%) 
b/l[c] e.e.[d]  
(%) 
1[e][f] (S)-1 mo 80 14 [6] 0.50 56 
2[f] (S)-1 mo 80 21 [13] 0.73 55 
3 (S)-1 mo 60 14 [10] 0.96 72 
4 (R)-2 mo 60 97 [69] 79 47 
5 (R)-2 di 60 91 [69] 55 42 
[a] Reactions were carried out on the scale of vinyl arene (0.25 mmol) in 2-
MeTHF (750 µL) and according to table, equation and ESI, unless otherwise 
noted. [b] Conversions and yields were determined by 1H NMR using 1-
methylnaphthalene as an internal standard [yield of isolated product in square 
brackets after acid-base extraction]. [c] b/l ratio determined by 1H NMR. [d] 
Enantiomeric excess determined by chiral HPLC. (S)-configured catalysts give 
(S)-configured product and vice versa. [e] Reaction performed in 2-butanone. [f] 
17 h.  
   
While the results with the F24-Phanephos catalysts (Table 2, 
Entries 4 and 5) are reasonably good in the context of this 
challenging reaction, the moderate enantioselectivity was not 
sufficient to be synthetically useful. We therefore checked to see 
if methoxycarbonylation could deliver any improvements (Table 
3). In all our previous work, methoxycarbonylation and 
hydroxycarbonylation of a given alkene have tended to give 
fairly similar regioselectivity and enantioselectivity. The results in 
Table 3 were therefore surprising for several reasons. Most 
catalysts show very disappointing activity with only [PdCl2((S)-
Xylyl-Phanephos)], (S)-1 mo, yielding any considerable product, 
with methanol as solvent. On top of this, (S)-1 mo was found to 
show excellent enantioselectivity (Table 3, Entries 1-7); this 
exceeds the selectivity observed with other styrene derivatives 
in previous work.[9a,b]  
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Table 3. Synthesis of prodrug Flurbiprofen methyl ester by enantioselective 
methoxycarbonylation using Pd-Phanephos catalysts. 
 
 
Entry[a] Catalyst T (o C) Product[b]  
(%) 
b/l[c] e.e.[d]  
(%) 
1 (S)-1 mo 60 98 1.17 91 
2[e] (S)-1 mo 60 > 99 1.37 93 
3[e][f] (S)-1 mo 60 59 1.27 92 
4[g] (S)-1 mo 45 83 [78] 1.31 95 
5 (S)-1 mo 40 81 [71] 1.39 95 
6[h] (S)-1 mo 40 61 1.54 96 
7[e] (S)-1 mo 40 81 1.63 96 
8[i][j] (S)-1 mo 40 0 - - 
9[j][k] (S)-1 mo 40 0 - - 
10[j][l] (S)-1 mo 40 0 - - 
11 (S)-1 mo 20 14 1.69 98 
12 (S)-1 di 40 27 1.62 96 
13 (R)-2 mo 40 8 > 100 51 
14[i] (R)-2 mo 40 7 > 100 58 
15[i] (R)-2 di 40 10 > 100 40 
16 (R)-3 mo 40 6 2.78 83 
17 (R)-3 di 40 8 3.38 74 
[a] Reactions were carried out on the scale of vinyl arene (0.25 mmol) in MeOH 
(750 µL) and according to table, equation and ESI, unless otherwise noted. [b] 
Conversions and yields were determined by 1H NMR using 1-
methylnaphthalene as an internal standard [yield of isolated product in square 
brackets], this includes regioisomerically pure branched products 39 % (entry 
4), 32 % (entry 5). [c] b/l ratio determined by 1H NMR. [d] Enantiomeric excess 
determined by chiral HPLC. (S)-configured catalysts give (S)-configured 
product and vice versa. [e] 70 bar CO. [f] No PTSA.H2O. [g] 1 mmol scale. [h] 
Al(OTf)3 (20 mol%) as acid. [i] 2-MeTHF solvent. [j] 10 equiv. MeOH. [k] 2-
butanone solvent. [l] PhMe as solvent.    
   
Isolation of pure branched ester (95 % e.e.) was possible by 
column chromatography, albeit in only moderate yields due to 
the lower regioselectivity of the reactions using (S)-1 mo. 
Increasing CO pressure increased regioselectivity to branched 
ester, but not considerably (Table 3, Entries 2 and 7). The low 
yields using F24-Phanephos catalysts (R)-2 mo/di are likely due 
to an unfavourable electronic effect retarding some part of the 
cycle to a much greater degree here than is observed with 
styrene itself. Consistent with this, the essentially isosteric 
phanephos based catalysts (R)-3 mo/di with meta 
dichlorophenyl groups also gave low yields relative to Xylyl-
Phanephos catalyst (S)-1 mo. Since enantioselection is a subtle 
event, the increases in enantioselectivity with this substrate, 
while striking, represent very small energy differences, but do 
reveal that this substrate is very nicely matched to the chiral 
pocket in the Pd/ phanephos catalysts. We have previously 
found that the concentration of methanol is significant to both 
productivity and selectivity in methoxycarbonylations. Neat 
methanol is beneficial for productivity in previous work.[9] Here 
this case is even more extreme, with other solvents using 
methanol as a reagent giving no product at all. This is not likely 
due to incompatibility in these solvents, since toluene, Me-THF 
and butanone have all given some product formation in 
carbonylation of another substrate using these catalysts.[9c] In 
addition, successful reactions in methanol tend to be 
accompanied by the formation of palladium black, while the 
reactions in Table 3, entries 8-10 were homogeneous solutions. 
It is quite likely that the active catalyst did not form in these 
solvents under these conditions. Some time ago we adopted the 
use of PTSA and LiCl as convenient solid sources of acid and 
chloride;[5c] this also gives better results when compared to the 
use of HCl, MsOH (inactive under these conditions) or Al(OTf)3 
(Table 3, entry 7 and ESI Table S-4) 
 
The highly enantioenriched Flurbiprofen methyl ester obtained 
was then subjected to acid-catalysed hydrolysis to (S)-
Flurbiprofen in near quantitative yield and without any 
considerable loss in enantioselectivity (Scheme 2).[1a]  
 
 
Scheme 2. Acid hydrolysis of enantio-enriched Flurbiprofen methyl ester to 
desired Flurbiprofen without any significant loss in enantioselectivity. Yield of 
isolated product in square bracket.  
Attempts were made to try to couple the two processes of cross-
coupling and carbonylation together in a tandem manner, re-
using the catalyst.[5b, 6c-f]  Unfortunately, a one-pot process 
involving hydroxycarbonylation failed to give any considerable 
product and returned unreacted vinyl arene. Cannula filtration 
between the two steps improved yields, with 50 % product 
detected (21 % isolated product) over the two steps. Similar 
issues were encountered with one-pot cross-coupling - 
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methoxycarbonylation, with the overall yield of pure branched 
isomer over the two steps not exceeding 17 % (see ESI).  
 
 
Scheme 3. Synthesis of Flurbiprofen and prodrug Flurbiprofen methyl ester 
from vinyl tosylate. Reaction conditions: (i) Cross-coupling: (R)-2 mo (1 
mol%), 19 h, > 99 % conversion, 73 % yield; (i*) Hydroxycarbonylation: 
Reaction mixture quenched with H2O (5 equv.), filtered by cannula, H2O (5 
equiv.) added to filtrate prior to reaction, 60 °C, 65 h, 69 % conversion, 69 % 
yield – Total isolated product from vinyl tosylate = 21 %, b:l = 6.08, e.e. = 41 % 
(R), R = H. (ii) Cross-Coupling: (S)-1 mo (1 mol%), 17 h, > 99 % conversion, 
90 % yield isolated with 2-fluorobiphenyl impurity; total product obtained = 
68 %; (ii*) Methoxycarbonylation: Isolated mixture re-charged with (S)-1 mo 
(1 mol%), MeOH, 40 °C, 17 h, 73 % conversion, 68 % yield – Total isolated 
product from vinyl tosylate = 40 %, b:l = 1.50, e.e. = 96 % (S), this includes 
regioisomerically pure branched product 17 %, R = Me.  
Conclusions 
A highly enantioselective synthesis of (S)-Flurbiprofen methyl 
ester in two steps from commercially available 4-bromo-2-fluoro-
1,1’-biphenyl has been achieved. [PdCl2((S)-Xylyl-Phanephos)], 
catalyst (S)-1 mo was used to accomplish both the novel 
Grignard cross-coupling of vinyl tosylate and the intermolecular 
methoxycarbonylation of vinyl arene. Significantly higher 
enantioselectivity is observed in the methoxycarbonylation of 
this substrate than styrene.  
Experimental Section 
Example procedure of methoxycarbonylation of 3-fluoro-4-phenylstyrene, 
Table 3, Entry 5: 
Lithium chloride (2.1 mg, 0.05 mmol), para-toluenesulfonic acid 
monohydrate (9.5 mg, 0. 50 mmol) and [PdCl2((S)-Xylyl-Phanephos)] (2.2 
mg, 0.0025 mmol) were weighed into a microwave vial equipped with a 
magnetic stirrer bar. The vial was sealed with a crimp cap and flushed 
with argon for 30 minutes. 3-fluoro-4-phenylstyrene (49.6 mg, 0.25 mmol) 
and 1-methylnaphthalene (30 µL, 0.21 mmol, internal standard) were 
added to a flame dried Schlenk flask under an inert atmosphere. 
Degassed methanol (750 µL) was then added to the Schlenk flask to 
make a solution. A t0 sample (approximately 10 µL) was taken and 
analysed by 1H NMR (to calibrate the ratio of internal standard to starting 
material). The solution containing the alkene and internal standard was 
added to the microwave vial via syringe. The crimp cap was pierced with 
two needles and quickly placed into an autoclave which had previously 
been placed under an argon atmosphere, before being opened under a 
flow of argon. The autoclave was sealed, purged three times with CO 
and then pressurised to 30 bar. The autoclave was then placed in an oil 
bath at 40 oC for 17 hours with constant stirring. Upon cooling to room 
temperature, the pressure was released slowly into a well-ventilated 
fume cupboard.  The mixture was analysed by taking a sample, diluting 
in CDCl3, and analysing by 1H NMR to assess the ratio between SM and 
desired product, as well as regioselectivity. Solvent was removed under 
reduced pressure and purification via column chromatography on silica 
gel (eluent petroleum ether:EtOAc, 100:0 to 90:10) gave branched 
methyl 2-(2-fluoro-biphenyl-4-yl)-propionate (20.7 mg, 32 %) as a white 
crystalline solid, linear methyl 3-(2-fluoro-biphenyl-4-yl)-propionate (3.6 
mg,  6 %) as a colourless oil and a mixture of both regioisomers (21.3 mg, 
33 %) as a colourless oil. The enantiomeric excess was determined by 
HPLC, using a Chiracel OJ column, 250 x 4.6 mm, 10 µm, 0.5 mL min-1, 
95:5 hexane : iso-propanol, tR[(-)-R] = 23 min, tR[(+)-S] = 27 min, tR[linear] 
= 46 min. 
Methyl 2-(2-fluoro-biphenyl-4-yl)-propionate: m.p. 39-40 °C {Lit.[14] 
40 °C}; δH (500 MHz, CDCl3): 7.56-7.51 (2H, m, CArH), 7.48-7.33 (4H, m, 
CArH), 7.17-7.09 (2H, m, CArH), 3.77 (1H, q, J = 7.2, -CHCH3), 3.71 (3H, 
s, -OCH3), 1.54 (3H, d, J = 7.2, -CHCH3); δF (376 MHz, CDCl3): -117.6; 
δC (125 MHz, CDCl3): 174.6 (CO2CH3), 159.8 (d, J = 248.3, CArF), 141.9 
(d, J = 7.7, CAr), 135.6 (CAr), 131.0 (d, J = 3.9, CArH), 129.1 (2C, d, J = 
2.9, CArH), 128.6 (2C, CArH), 128.0 (d, J = 13.6, CAr), 127.8 (CArH), 123.7 
(d, J = 3.3, CArH), 115.4 (d, J = 23.6, CArH), 52.4 (-OCH3), 45.1 (-CHCH3), 
18.6 (-CHCH3); m/z HRMS (ESI+) C16H16FO2 ([M+H]+) requires 259.1129; 
found 259.1126 (-1.2 ppm). Anal. Calcd for C16H15FO2: C, 74.40; H, 5.85; 
Found: C, 74.51; H, 5.99. These data are consistent with those reported 
in literature.[15] [α]D20 = + 46.2 (c = 1.00, CHCl3, e.e. = 95 % (S)) {lit.[1a] 
[α]D20  = - 39.2 (c = 1.50, CHCl3, e.e. = 76 % (R))}.  
Methyl 3-(2-fluoro-biphenyl-4-yl)-propionate: νmax (ATR) 1732 (s), 
1485 (w), 1416 (m), 1265 (w) 1196 (m), 1153 (m), 1126 (m), 827 (w), 766 
(s); δH (500 MHz, CDCl3): 7.56-7.52 (2H, m, CArH), 7.47-7.42 (2H, m, 
CArH), 7.40-7.33 (2H, m, CArH), 7.06 (1H, dd, J = 7.8, 1.7, CArH), 7.02 (1H, 
dd, J = 11.5, 1.7, CArH), 3.70 (3H, s, -OCH3), 3.00 (2H, t, J = 7.8, CArCH2), 
2.68 (2H, t, J = 7.8, CArCH2CH2); δF (376 MHz, CDCl3): -118.2; δC (125 
MHz, CDCl3): 173.2 (CO2CH3), 159.8 (d, J = 248.0, CArF), 142.2 (d, J = 
7.7, CAr), 135.8 (CAr), 130.8 (d, J = 3.9, CArH), 129.0 (2C, d, J = 3.0, 
CArH), 128.5 (2C, CArH), 127.7 (CArH), 127.0 (d, J = 13.5, CAr), 124.4 (d, J 
= 3.2, CArH), 116.0 (d, J = 22.8, CArH), 51.9 (-OCH3), 35.4 (CArCH2CH2), 
30.4 (CArCH2CH2); m/z HRMS (ESI+) C16H15FO2Na+ ([M+Na]+) requires 
281.0948; found 281.0944 (-1.4 ppm).       
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An enantioselective synthesis of (S)-Flurbiprofen is described: The same type of Pd 
complex has been found to be useful in making the vinyl arene substrate, and as 
catalyst for a highly enantioselective alkene carbonylation.  
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